Morgan Stanley downgrades Sonova on 'near peak' valuation
** Morgan Stanley cuts Swiss hearing aid maker Sonova SOON.S to "equal-weight" from "overweight", seeing little upside to the stock as its value has increased sharply from November lows
** Reasons for the previous rating are now factored in, with new product launch well expected and a deal with Costco offering only a low to mid single-digit potential EPS upside, MS says
** The broker notes Sonova's stock has surged 42% from its mid-November lows and it is trading at "near peak" prices
** Out of 19 analysts that cover Sonova, seven rate the stock "strong buy" or "buy", nine "hold" and three "strong sell" or "sell"
Reporting by Tristan Veyet
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
